Flagship Pioneering. has filed a patent for fusosome compositions and methods that deliver biologic agents to target cell cytoplasm. The composition includes lipid bilayer, cytosol, and specific fusogens like Nipah virus proteins. The fusosomes do not contain a nucleus, with minimal viral capsid protein. GlobalData’s report on Flagship Pioneering gives a 360-degree view of the company including its patenting strategy. Buy the report here.

According to GlobalData’s company profile on Flagship Pioneering, Cancer treatment biomarkers was a key innovation area identified from patents. Flagship Pioneering's grant share as of January 2024 was 10%. Grant share is based on the ratio of number of grants to total number of patents.

Fusosome composition for delivering biologic agents to target cells

Source: United States Patent and Trademark Office (USPTO). Credit: Flagship Pioneering Inc

A patent application (Publication Number: US20240033227A1) describes a fusosome composition that includes multiple fusosomes derived from a source cell. These fusosomes consist of a lipid bilayer, a lumen containing cytosol from the source cell, an exogenous or overexpressed fusogen (such as specific viral proteins), and cargo. Notably, the fusosomes do not contain a nucleus, and the viral capsid protein content is minimal. Additionally, some fusosomes may include a targeting moiety specific to certain cell surface markers, enabling precise delivery to skin cells, cardiomyocytes, hepatocytes, and other cell types. The fusosomes may vary in size and can be derived from various cell types, including neutrophils, stem cells, and neurons.

Furthermore, the patent application outlines the use of this fusosome composition in pharmaceutical compositions for delivering therapeutic agents to subjects. By administering these compositions, the cargo can be effectively delivered to the target cells, offering a potential method for targeted drug delivery. The fusosome composition can be tailored to include specific fusogens and cargoes, enhancing its versatility for various applications. The absence of viral capsid proteins in the fusosomes is a notable feature, ensuring the safety and efficacy of the delivery system. Overall, the patent application presents a novel approach to drug delivery using fusosomes, highlighting their potential in precision medicine and targeted therapy.

To know more about GlobalData’s detailed insights on Flagship Pioneering, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.